Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice

Augusto Pessina, Valentina Coccè, Luisa Pascucci, Arianna Bonomi, Loredana Cavicchini, Francesca Sisto, Maura Ferrari, Emilio Ciusani, Antonio Crovace, Maria Laura Falchetti, Sonia Zicari, Arnaldo Caruso, Stefania Navone, Giovanni Marfia, Anna Benetti, Piero Ceccarelli, Eugenio Parati, Giulio Alessandri

Research output: Contribution to journalArticle

Abstract

Current leukaemia therapy focuses on increasing chemotherapy efficacy. Mesenchymal stromal cells (MSCs) have been proposed for carrying and delivery drugs to improve killing of cancer cells. We have shown that MSCs loaded with Paclitaxel (PTX) acquire a potent anti-tumour activity. We investigated the effect of human MSCs (hMSCs) and mouse SR4987 loaded with PTX (hMSCsPTX and SR4987PTX) on MOLT-4 and L1210, two leukaemia cell (LCs) lines of human and mouse origin, respectively. SR4987PTX and hMSCsPTX showed strong anti-LC activity. hMSCsPTX, co-injected with MOLT-4 cells or intra-tumour injected into established subcutaneous MOLT-4 nodules, strongly inhibited growth and angiogenesis. In BDF1-mice-bearing L1210, the intraperitoneal administration of SR4987PTX doubled mouse survival time. In vitro, both hMSCs and hMSCsPTX released chemotactic factors, bound and formed rosettes with LCs. In ultrastructural analysis of rosettes, hMSCsPTX showed no morphological alterations while the attached LCs were apoptotic and necrotic. hMSCs and hMSCsPTX released molecules that reduced LC adhesion to microvascular endothelium (hMECs) and down-modulated ICAM1 and VCAM1 on hMECs. Priming hMSCs with PTX is a simple procedure that does not require any genetic cell manipulation. Once the effectiveness of hMSCsPTX on established cancers in mice is proven, this procedure could be proposed for leukaemia therapy in humans.

Original languageEnglish
Pages (from-to)766-778
Number of pages13
JournalBritish Journal of Haematology
Volume160
Issue number6
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Paclitaxel
Mesenchymal Stromal Cells
Leukemia
Neoplasms
Leukemia L1210
Chemotactic Factors
Cell Adhesion
Endothelium
Drug Therapy
Cell Line
Therapeutics
Growth
Pharmaceutical Preparations

Keywords

  • Leukaemia
  • Mesenchymal stem cells
  • Paclitaxel

ASJC Scopus subject areas

  • Hematology

Cite this

Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice. / Pessina, Augusto; Coccè, Valentina; Pascucci, Luisa; Bonomi, Arianna; Cavicchini, Loredana; Sisto, Francesca; Ferrari, Maura; Ciusani, Emilio; Crovace, Antonio; Falchetti, Maria Laura; Zicari, Sonia; Caruso, Arnaldo; Navone, Stefania; Marfia, Giovanni; Benetti, Anna; Ceccarelli, Piero; Parati, Eugenio; Alessandri, Giulio.

In: British Journal of Haematology, Vol. 160, No. 6, 03.2013, p. 766-778.

Research output: Contribution to journalArticle

Pessina, A, Coccè, V, Pascucci, L, Bonomi, A, Cavicchini, L, Sisto, F, Ferrari, M, Ciusani, E, Crovace, A, Falchetti, ML, Zicari, S, Caruso, A, Navone, S, Marfia, G, Benetti, A, Ceccarelli, P, Parati, E & Alessandri, G 2013, 'Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice', British Journal of Haematology, vol. 160, no. 6, pp. 766-778. https://doi.org/10.1111/bjh.12196
Pessina, Augusto ; Coccè, Valentina ; Pascucci, Luisa ; Bonomi, Arianna ; Cavicchini, Loredana ; Sisto, Francesca ; Ferrari, Maura ; Ciusani, Emilio ; Crovace, Antonio ; Falchetti, Maria Laura ; Zicari, Sonia ; Caruso, Arnaldo ; Navone, Stefania ; Marfia, Giovanni ; Benetti, Anna ; Ceccarelli, Piero ; Parati, Eugenio ; Alessandri, Giulio. / Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice. In: British Journal of Haematology. 2013 ; Vol. 160, No. 6. pp. 766-778.
@article{4e03fa5256a1458ab95cd47a972f7c4b,
title = "Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice",
abstract = "Current leukaemia therapy focuses on increasing chemotherapy efficacy. Mesenchymal stromal cells (MSCs) have been proposed for carrying and delivery drugs to improve killing of cancer cells. We have shown that MSCs loaded with Paclitaxel (PTX) acquire a potent anti-tumour activity. We investigated the effect of human MSCs (hMSCs) and mouse SR4987 loaded with PTX (hMSCsPTX and SR4987PTX) on MOLT-4 and L1210, two leukaemia cell (LCs) lines of human and mouse origin, respectively. SR4987PTX and hMSCsPTX showed strong anti-LC activity. hMSCsPTX, co-injected with MOLT-4 cells or intra-tumour injected into established subcutaneous MOLT-4 nodules, strongly inhibited growth and angiogenesis. In BDF1-mice-bearing L1210, the intraperitoneal administration of SR4987PTX doubled mouse survival time. In vitro, both hMSCs and hMSCsPTX released chemotactic factors, bound and formed rosettes with LCs. In ultrastructural analysis of rosettes, hMSCsPTX showed no morphological alterations while the attached LCs were apoptotic and necrotic. hMSCs and hMSCsPTX released molecules that reduced LC adhesion to microvascular endothelium (hMECs) and down-modulated ICAM1 and VCAM1 on hMECs. Priming hMSCs with PTX is a simple procedure that does not require any genetic cell manipulation. Once the effectiveness of hMSCsPTX on established cancers in mice is proven, this procedure could be proposed for leukaemia therapy in humans.",
keywords = "Leukaemia, Mesenchymal stem cells, Paclitaxel",
author = "Augusto Pessina and Valentina Cocc{\`e} and Luisa Pascucci and Arianna Bonomi and Loredana Cavicchini and Francesca Sisto and Maura Ferrari and Emilio Ciusani and Antonio Crovace and Falchetti, {Maria Laura} and Sonia Zicari and Arnaldo Caruso and Stefania Navone and Giovanni Marfia and Anna Benetti and Piero Ceccarelli and Eugenio Parati and Giulio Alessandri",
year = "2013",
month = "3",
doi = "10.1111/bjh.12196",
language = "English",
volume = "160",
pages = "766--778",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "6",

}

TY - JOUR

T1 - Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice

AU - Pessina, Augusto

AU - Coccè, Valentina

AU - Pascucci, Luisa

AU - Bonomi, Arianna

AU - Cavicchini, Loredana

AU - Sisto, Francesca

AU - Ferrari, Maura

AU - Ciusani, Emilio

AU - Crovace, Antonio

AU - Falchetti, Maria Laura

AU - Zicari, Sonia

AU - Caruso, Arnaldo

AU - Navone, Stefania

AU - Marfia, Giovanni

AU - Benetti, Anna

AU - Ceccarelli, Piero

AU - Parati, Eugenio

AU - Alessandri, Giulio

PY - 2013/3

Y1 - 2013/3

N2 - Current leukaemia therapy focuses on increasing chemotherapy efficacy. Mesenchymal stromal cells (MSCs) have been proposed for carrying and delivery drugs to improve killing of cancer cells. We have shown that MSCs loaded with Paclitaxel (PTX) acquire a potent anti-tumour activity. We investigated the effect of human MSCs (hMSCs) and mouse SR4987 loaded with PTX (hMSCsPTX and SR4987PTX) on MOLT-4 and L1210, two leukaemia cell (LCs) lines of human and mouse origin, respectively. SR4987PTX and hMSCsPTX showed strong anti-LC activity. hMSCsPTX, co-injected with MOLT-4 cells or intra-tumour injected into established subcutaneous MOLT-4 nodules, strongly inhibited growth and angiogenesis. In BDF1-mice-bearing L1210, the intraperitoneal administration of SR4987PTX doubled mouse survival time. In vitro, both hMSCs and hMSCsPTX released chemotactic factors, bound and formed rosettes with LCs. In ultrastructural analysis of rosettes, hMSCsPTX showed no morphological alterations while the attached LCs were apoptotic and necrotic. hMSCs and hMSCsPTX released molecules that reduced LC adhesion to microvascular endothelium (hMECs) and down-modulated ICAM1 and VCAM1 on hMECs. Priming hMSCs with PTX is a simple procedure that does not require any genetic cell manipulation. Once the effectiveness of hMSCsPTX on established cancers in mice is proven, this procedure could be proposed for leukaemia therapy in humans.

AB - Current leukaemia therapy focuses on increasing chemotherapy efficacy. Mesenchymal stromal cells (MSCs) have been proposed for carrying and delivery drugs to improve killing of cancer cells. We have shown that MSCs loaded with Paclitaxel (PTX) acquire a potent anti-tumour activity. We investigated the effect of human MSCs (hMSCs) and mouse SR4987 loaded with PTX (hMSCsPTX and SR4987PTX) on MOLT-4 and L1210, two leukaemia cell (LCs) lines of human and mouse origin, respectively. SR4987PTX and hMSCsPTX showed strong anti-LC activity. hMSCsPTX, co-injected with MOLT-4 cells or intra-tumour injected into established subcutaneous MOLT-4 nodules, strongly inhibited growth and angiogenesis. In BDF1-mice-bearing L1210, the intraperitoneal administration of SR4987PTX doubled mouse survival time. In vitro, both hMSCs and hMSCsPTX released chemotactic factors, bound and formed rosettes with LCs. In ultrastructural analysis of rosettes, hMSCsPTX showed no morphological alterations while the attached LCs were apoptotic and necrotic. hMSCs and hMSCsPTX released molecules that reduced LC adhesion to microvascular endothelium (hMECs) and down-modulated ICAM1 and VCAM1 on hMECs. Priming hMSCs with PTX is a simple procedure that does not require any genetic cell manipulation. Once the effectiveness of hMSCsPTX on established cancers in mice is proven, this procedure could be proposed for leukaemia therapy in humans.

KW - Leukaemia

KW - Mesenchymal stem cells

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84874684335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874684335&partnerID=8YFLogxK

U2 - 10.1111/bjh.12196

DO - 10.1111/bjh.12196

M3 - Article

C2 - 23293837

AN - SCOPUS:84874684335

VL - 160

SP - 766

EP - 778

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -